OBJECTIVE: Folates exist as a fluctuating pool of polyglutamated metabolites that may serve as a clinical marker of methotrexate (MTX) activity. This study was undertaken to evaluate circulating folate content and folate polyglutamate distribution in juvenile idiopathic arthritis (JIA) patients and in a cell culture model based on MTX exposure and folate supply. METHODS: Blood, plasma, and red blood cell (RBC) measurements of MTX and folates were obtained from previously published data sets and an additional analysis of JIA patients receiving MTX (n = 98) and those not receiving MTX (n = 78). Erythroblastoid cells maintained in culture were exposed to MTX and grown under varying levels of folic acid supplementation. Samples were analyzed for cellular folate and MTX content. RESULTS: Circulating folate levels were lower in JIA patients receiving MTX, with reduced levels of blood, plasma, and RBC 5-methyl-tetrahydrofolate (5mTHF) (P < 0.0001). Average polyglutamate chain length (Gluavg ) of RBC 5mTHF was elevated in JIA patients receiving MTX (median ± interquartile range 5.63 ± 0.15 versus 5.54 ± 0.11 in those not receiving MTX; P < 0.001) and correlated with both RBC MTX accumulation (P = 0.02) and reduced plasma 5mTHF levels (P = 0.008). MTX exposure and folate deprivation in erythroblastoid cells resulted in a depletion of bioactive folate species that was associated with a shift to higher Gluavg values for several species, most notably tetrahydrofolate (THF) and 5,10-methylene-tetrahydrofolate (CH2 THF). Increased Gluavg resulted from the depletion of short-chain and the accumulation of long-chain glutamate species. CONCLUSION: Our findings indicate that folate content and polyglutamate distribution are responsive markers of MTX activity and folate supply in vivo and in vitro, and may provide novel clinical markers of pharmacologic activity of MTX.
OBJECTIVE:Folates exist as a fluctuating pool of polyglutamated metabolites that may serve as a clinical marker of methotrexate (MTX) activity. This study was undertaken to evaluate circulating folate content and folate polyglutamate distribution in juvenile idiopathic arthritis (JIA) patients and in a cell culture model based on MTX exposure and folate supply. METHODS: Blood, plasma, and red blood cell (RBC) measurements of MTX and folates were obtained from previously published data sets and an additional analysis of JIA patients receiving MTX (n = 98) and those not receiving MTX (n = 78). Erythroblastoid cells maintained in culture were exposed to MTX and grown under varying levels of folic acid supplementation. Samples were analyzed for cellular folate and MTX content. RESULTS: Circulating folate levels were lower in JIA patients receiving MTX, with reduced levels of blood, plasma, and RBC 5-methyl-tetrahydrofolate (5mTHF) (P < 0.0001). Average polyglutamate chain length (Gluavg ) of RBC 5mTHF was elevated in JIA patients receiving MTX (median ± interquartile range 5.63 ± 0.15 versus 5.54 ± 0.11 in those not receiving MTX; P < 0.001) and correlated with both RBC MTX accumulation (P = 0.02) and reduced plasma 5mTHF levels (P = 0.008). MTX exposure and folate deprivation in erythroblastoid cells resulted in a depletion of bioactive folate species that was associated with a shift to higher Gluavg values for several species, most notably tetrahydrofolate (THF) and 5,10-methylene-tetrahydrofolate (CH2 THF). Increased Gluavg resulted from the depletion of short-chain and the accumulation of long-chain glutamate species. CONCLUSION: Our findings indicate that folate content and polyglutamate distribution are responsive markers of MTX activity and folate supply in vivo and in vitro, and may provide novel clinical markers of pharmacologic activity of MTX.
Authors: Nicolino Ruperto; Kevin J Murray; Valeria Gerloni; Nico Wulffraat; Sheila Knupp Feitosa de Oliveira; Fernanda Falcini; Pavla Dolezalova; Maria Alessio; Ruben Burgos-Vargas; Fabrizia Corona; Richard Vesely; Helen Foster; Joyce Davidson; Francesco Zulian; Line Asplin; Eileen Baildam; Julia Garcia Consuegra; Huri Ozdogan; Rotraud Saurenmann; Rik Joos; Angela Pistorio; Pat Woo; Alberto Martini Journal: Arthritis Rheum Date: 2004-07
Authors: S L Morgan; J E Baggott; W H Vaughn; J S Austin; T A Veitch; J Y Lee; W J Koopman; C L Krumdieck; G S Alarcón Journal: Ann Intern Med Date: 1994-12-01 Impact factor: 25.391
Authors: Rakesh K Singh; Leon van Haandel; Daniel P Heruth; Shui Q Ye; J Steven Leeder; Mara L Becker; Ryan S Funk Journal: J Pharmacol Exp Ther Date: 2018-02-02 Impact factor: 4.030
Authors: Rakesh K Singh; Leon van Haandel; Paul Kiptoo; Mara L Becker; Teruna J Siahaan; Ryan S Funk Journal: Eur J Pharmacol Date: 2019-04-02 Impact factor: 4.432
Authors: Laura B Ramsey; Halima Moncrieffe; Chelsey N Smith; Marc Sudman; Miranda C Marion; Carl D Langefeld; Mara L Becker; Susan D Thompson Journal: ACR Open Rheumatol Date: 2019-03-15
Authors: Natanja Oosterom; Robert de Jonge; Desiree E C Smith; Rob Pieters; Wim J E Tissing; Marta Fiocco; Bertrand D van Zelst; Marry M van den Heuvel-Eibrink; Sandra G Heil Journal: PLoS One Date: 2019-09-17 Impact factor: 3.240